走进利拉鲁肽 更多 >>
继日本中央社会保险医疗委员会批准了Victoza®（利拉鲁肽）的定价之后，诺和诺德制药公司计划将尽快在当地市场推出这种产品。诺和诺德表示，Victoza®是首个在日本获准上市的GLP-1类药物，既可以单独用药，也可以作为辅助药物与磺脲类降糖药(SU)联用。
Glucagon-like peptide-1 receptor agonists in type 2 diabetes:a meta-analysis of randomized clinical trials
最近发表于《European Journal of Endocrinology》的文章报道，一项纳入了21项随机对照试验、 3,053名患者的荟萃分析结果显示，GLP-1激动剂改善HbA1c和餐后血糖的效果更好，低血糖风险更小，心血管事件也没有增加。
对于磺脲类和双胍类药物治疗效果不佳的患者，继用GLP-1激动剂的效果可与胰岛素媲美。目前的数据也显示，每日一次使用的liraglutide的耐受性和有效性不逊于每日两次的exenatide。
OBJECTIVE：
The role of Glucagon-Like Peptide-1 (GLP-1) receptor agonists in the treatment of type 2 diabetes is debated; many recent trials, which were not included in previous meta-analyses, could add relevant information.
DESIGN AND METHODS：
All available randomized controlled trials (RCTs), either published or unpublished, performed in type 2 diabetic patients with GLP-1 receptor agonists (exenatide and liraglutide), with a duration>12 weeks were meta-analysed for HbA1c, BMI, hypoglycaemia, and other adverse events.
RESULTS AND CONCLUSIONS：
A total of 21 RCTs (6 of which unpublished), enrolling 5,429 and 3,053 patients (with GLP-1 receptor agonists and active comparator or placebo, respectively), was retrieved and included in the analysis. GLP-1 receptor agonists determine a significant improvement of HbA1c in comparison with placebo (-1.0[-1.1:-0.8], p<0.001), with a low risk of hypoglycaemia. There is no evidence of increased cardiovascular risk with the use of GLP-1 receptor agonists. GLP-1 receptor agonists, which induce weight loss, are associated with gastrointestinal side effects. GLP-1 receptor agonists are effective in reducing HbA1c and postprandial glucose. In patients failing to sulphonylureas and/or metformin, GLP-1 receptor agonists are similarly effective as insulin. Available data suggest that the efficacy and tolerability of the novel agent, liraglutide, which is adequate for once-a-day administration, are comparable to those of exenatide bis in die.
编辑: helen
以下网友留言只代表网友个人观点，不代表网站观点
